CJC-1295 No DAC + Ipamorelin 5mg/5mg

Description

CJC-1295 (without DAC) 5 mg + Ipamorelin 5 mg is a dual-peptide research formulation containing 10 mg of total peptide material. This combination pairs a modified growth hormone-releasing hormone analog with a selective growth hormone secretagogue receptor agonist, allowing researchers to study two complementary neuroendocrine signaling pathways within a single experimental system.

CJC-1295 without DAC, also known as Modified GRF 1-29, is a shortened and structurally modified analog of growth hormone-releasing hormone. It is designed to provide improved stability in laboratory models while retaining activity at the GHRH receptor.

Ipamorelin is a selective pentapeptide agonist of the growth hormone secretagogue receptor, commonly known as GHS-R1a. It is used in research involving ghrelin receptor activity, intracellular calcium signaling, endocrine regulation, and downstream cellular responses.

The combined formulation allows investigators to examine receptor crosstalk between the GHRH and GHS-R pathways. Laboratory studies may evaluate cyclic adenosine monophosphate production, calcium mobilization, signal integration, temporal response patterns, and changes in gene expression following coordinated receptor activation.

The 10 mg presentation contains 5 mg of CJC-1295 without DAC and 5 mg of Ipamorelin. It is suitable for pilot studies, concentration-response testing, receptor signaling assays, time-course experiments, and comparative neuroendocrine research.

Each PEPTEX Labs production lot is manufactured under controlled conditions and subject to quality testing. Testing may include HPLC purity analysis, mass spectrometry identity verification, net-content testing, and endotoxin analysis, depending on the individual batch.

This product is supplied exclusively for qualified laboratory research. It is not intended for human or veterinary use, clinical administration, or therapeutic application.